Amarin Corp Plc (AMRN)

[ilovetech]

M - There is a concensus around improving patient compliance, which is most often achieved with more convenient, if possible also cheaper options. Next time I speak to my brother, I'll ask him to rattle off a few examples, as I'm sure his list would be overkill. For example, Boniva was a once a week bone density drug. Not sure if there was a once a day version earlier. Even at once a week, the market research clearly showed a strong case to come out with a once a month version. Also, there was a very viable competitor with a once a week version. So a once a month Boniva was successfully launched. It's a common strategy and it works. BTW - At times the new more convenient option has cost more at launch, and insurers have been willing to cover the cost to foster compliance. In the meantime, ROW is for the taking, but I'm just making a case for BP to include U.S. future sales by way of V 2.0.

ILT